Anti-cd47 Monoclonal Antibody Hu5f9-g4
Anti-cd47 Monoclonal Antibody Hu5f9-g4 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-cd47 Monoclonal Antibody Hu5f9-g4 is under investigation in clinical trial NCT02953782 (Trial of Anti-cd47 Monoclonal Antibody Hu5f9-g4 (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
| Trade Name | Anti-cd47 Monoclonal Antibody Hu5f9-g4 |
| Generic | Magrolimab |
| Magrolimab Other Names | Anti-cd47 monoclonal antibody hu5f9-g4, Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2, Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer, Magrolimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-cd47 Monoclonal Antibody Hu5f9-g4
